General Proximity has built the OmniTAC platform, a mechanism-agnostic proximity discovery engine that scans the "effectome"—effector proteins that can modulate disease-relevant targets. The company is advancing multiple preclinical programs across oncology, cardiometabolic disease, neurodegeneration, and longevity. Its track record includes over $20 million raised to date, five "Golden Ticket" awards from major pharma companies, and non-dilutive grants from ARPA-H and the NIH's National Cancer Institute. General Proximity also announced a strategic multi-target collaboration with Daiichi Sankyo. The company is headquartered in San Francisco and is positioning its platform to unlock targets previously considered beyond the reach of medicine.

Total raised

$16M

Funding rounds

2

Latest round

Seed

Latest activity

Jan 2025